1. Home
  2. |Professionals
  3. |Christopher Dumont

Christopher Dumont

Counsel
Counsel
Y2R1bW9udEBjcm93ZWxsLmNvbQ==
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Christopher Dumont is a counsel in Crowell & Moring’s Brussels office and is a member of the Intellectual Property Group.

Christopher advises and assists clients on a wide range of IP/IT law matters, both contentious and non-contentious, focusing on life sciences litigation. He has extensive experience advising and litigating complex trademark and patent disputes such as SPCs, SPC manufacturing waivers, and the Bolar exemption. He has also developed strong knowledge in advisory and litigation matters before European courts, regarding, among other things, data exclusivity and market protection issues related to pharmaceuticals.

Before joining Crowell as a senior associate in February 2022, Christopher worked for three and a half years at a leading Belgian law firm.

Career & Education

    • Catholic University of Leuven, B.A., honours program, 2015
    • Catholic University of Leuven, J.D., honours program, 2017
    • Catholic University of Leuven, LL.M., intellectual property law, 2018
    • Catholic University of Leuven, B.A., honours program, 2015
    • Catholic University of Leuven, J.D., honours program, 2017
    • Catholic University of Leuven, LL.M., intellectual property law, 2018

    • Belgium
    • European Court
    • Belgium
    • European Court

    • Dutch
    • English
    • French
    • Dutch
    • English
    • French
Kristof Roox and Christopher Dumont are able to deliver within tight deadlines. They bring innovative ways to help customers, excellent collaboration within a group of customers. Clear when conveying information and summaries.

— Legal 500, 2024

Christopher's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights

Representative Matters

  • Assisting leading pharmaceutical companies in preliminary injunction proceedings regarding generic versions of blockbuster medicinal products.
  • Assisting one of the largest tobacco companies in a multilayered cross-border trademark litigation against a spread-out network of infringers.
  • Assisting a leading financial company in the development and maintenance of their trademark portfolio.
  • Assisting a major Belgian book publisher in complex litigation and investigation by court-appointed expert concerning the publishing and audiovisual rights attached to a graphic character.
  • Negotiating a global software license for a consortium of companies in the recycling industry.
  • Assisting a European public-private partnership with the supply of data protection and related services.

Christopher's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights

Recognition

IAM Patent 1000: Litigation and Transactions, Recommended, 2025

Christopher's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights

Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

Client Alert | 2 min read | 03.12.26

The EU Pharma Package: Formal Adoption in Sight

Publication | 02.03.26

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Firm News | 7 min read | 01.09.26

Crowell & Moring Elects 15 New Partners, Promotes One to Senior Counsel and 26 to Counsel

View All Insights

Practices

Industries

Christopher's Insights

Client Alert | 5 min read | 03.22.26

EU Pharma Package: Regulatory Data Protection Compromise Proposal

In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions....

View All Insights